Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome

References

• Tiotiu A, Chong Neto H, Bikov A, et al. Impact of the COVID-19 pandemic on the management of chronic noninfectious respiratory diseases. Expert Rev Respir Med. 2021;15(8):1035–1048. doi:10.1080/17476348.2021.1951707
   PubMed Web of Science ®Google Scholar
• Sabetkish N, Rahmani A. The overall impact of COVID-19 on healthcare during the pandemic: a multidisciplinary point of view. Health Sci Rep. 2021;4:e386. doi:10.1002/hsr2.386
   PubMedGoogle Scholar
• Robinson PC, Yazdany J. The COVID-19 global rheumatology alliance: collecting data in a pandemic. Nat Rev Rheumatol. 2020;16(6):293–294. doi:10.1038/s41584-020-0418-0
   PubMed Web of Science ®Google Scholar
• Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. 2020;39(7):2055–2062. doi:10.1007/s10067-020-05073-9
   PubMed Web of Science ®Google Scholar
• Ceribelli A, Motta F, De Santis M, et al. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. J Autoimmun. 2020;109:102442. doi:10.1016/j.jaut.2020.102442
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Flohr C, Simon D, et al. European task force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis. J Eur Acad Dermatol Venereol. 2020;34(6):e241–e242. doi:10.1111/jdv.16411
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Agache I, Akdis CA, et al. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: an EAACI statement. Allergy. 2020;75(11):2764–2774. doi:10.1111/all.14407
   PubMed Web of Science ®Google Scholar
• Klimek L, Pfaar O, Worm M, et al. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in co-operation with the German, Austrian, and Swiss ARIA groupsG, and the European Academy of Allergy and Clinical Immunology (EAACI)H. Allergol Select. 2020;4:53–68. doi:10.5414/ALX02166E
   PubMedGoogle Scholar
• Ricardo JW, Lipner SR. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. Dermatol Ther. 2020;33(5):e13687. doi:10.1111/dth.13687
   PubMed Web of Science ®Google Scholar
• Morais-Almeida M, Aguiar R, Martin B, et al. COVID-19, asthma, and biological therapies: what we need to know. World Allergy Organ J. 2020;13(5):100126. doi:10.1016/j.waojou.2020.100126
   PubMed Web of Science ®Google Scholar
• Poddighe D, Brambilla I, Licari A, Marseglia GL. Omalizumab in the therapy of pediatric asthma. Recent Pat Inflamm Allergy Drug Discov. 2018;12(2):103–109. doi:10.2174/1872213X12666180430161351
   PubMed Web of Science ®Google Scholar
• Lommatzsch M, Stoll P, Virchow JC. COVID-19 in a patient with severe asthma treated with Omalizumab. Allergy. 2020;75(10)::2705–2708. doi:10.1111/all.14456
   PubMed Web of Science ®Google Scholar
• Criado PR, Criado RFJ, Pincelli TP, Yoshimoto TA, Naufal GGA, Abdalla BMZ. Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab. Int J Dermatol. 2020;59(10):1294–1295. doi:10.1111/ijd.15134
   PubMed Web of Science ®Google Scholar
• Liu S, Zhi Y, Ying S. COVID-19 and asthma: reflection during the pandemic. Clin Rev Allergy Immunol. 2020;59(1):78–88. doi:10.1007/s12016-020-08797-3
   PubMed Web of Science ®Google Scholar
• Criado PR, Pagliari C, Criado RFJ, Marques GF, Belda W Jr. What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2? Dermatol Ther. 2020;33:e14068. doi:10.1111/dth.14068
   PubMed Web of Science ®Google Scholar
• Abdelmaksoud A, Goldust M, Vestita M. Omalizumab and COVID-19 treatment: could it help? Dermatol Ther. 2020;33:e13792. doi:10.1111/dth.13792
   PubMed Web of Science ®Google Scholar
• Baldallo C, León Román JC, Serón D, et al. COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab. Nefrologia. 2021;41(3):354–356. doi:10.1016/j.nefroe.2020.07.003
   Web of Science ®Google Scholar
• Ayhan E, Öztürk M, An İ, Bekçibaşi M. COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases. Int J Dermatol. 2021;60(2):253–254. doi:10.1111/ijd.15379
   PubMed Web of Science ®Google Scholar
• Eger K, Hashimoto S, Braunstahl GJ, et al. Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy. Respir Med. 2020;177:106287. doi:10.1016/j.rmed.2020.106287
   PubMed Web of Science ®Google Scholar
• Passante M, Napolitano M, Dastoli S, et al. Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19. Dermatol Ther. 2021. doi:10.1111/dth.15111
   PubMed Web of Science ®Google Scholar
• Muntean IA, Pintea I, Bocsan IC, Dobrican CT, Deleanu D. COVID-19 disease leading to chronic spontaneous urticaria exacerbation: a Romanian retrospective study. Healthcare. 2021;9(9):1144. doi:10.3390/healthcare9091144
   Web of Science ®Google Scholar
• Aksu K, Demir Ş, Topel M, et al. COVID-19 in patients with severe asthma using biological agents. Tuberk Toraks. 2021;69(3):433–436. doi:10.5578/tt.20219721
   PubMed Web of Science ®Google Scholar
• Abduelmula A, Georgakopoulos JR, Mufti A, et al. Incidence of COVID-19 in patients with chronic idiopathic urticaria and asthma on Omalizumab: a multicentre retrospective cohort study. J Cutan Med Surg. 2021:120347542110497. doi:10.1177/12034754211049707
   Web of Science ®Google Scholar
• Bostan E, Zaid F, Karaduman A, et al. The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: a cross-sectional, comparative study. J Cosmet Dermatol. 2021;20(11):3369–3375. doi:10.1111/jocd.14484
   PubMed Web of Science ®Google Scholar
• Renner A, Marth K, Patocka K, Pohl W. COVID-19 in a severe eosinophilic asthmatic receiving benralizumab - a case study. J Asthma. 2021;58(9):1270–1272. doi:10.1080/02770903.2020.1781165
   PubMed Web of Science ®Google Scholar
• Renner A, Marth K, Patocka K, Idzko M, Pohl W. COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth. ERJ Open Res. 2020;6(4):00457–2020. doi:10.1183/23120541.00457-2020
   PubMedGoogle Scholar
• Heffler E, Detoraki A, Contoli M, et al.; SANI Working Group. COVID-19 in Severe Asthma Network in Italy (SANI) patients: clinical features, impact of comorbidities and treatments. Allergy. 2021;76(3):887–892. doi:10.1111/all.14532
   PubMed Web of Science ®Google Scholar
• Kroes JA, Zielhuis SW, Bethlehem C, Ten Brinke A, Van Roon EN. Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report. Eur J Hosp Pharm. 2021. doi:10.1136/ejhpharm-2020-002660
   PubMedGoogle Scholar
• Schmid-Grendelmeier P, Steiger P, Naegeli MC, et al. Benralizumab for severe DRESS in two COVID-19 patients. J Allergy Clin Immunol Pract. 2021;9(1):481–483. doi:10.1016/j.jaip.2020.09.039
   PubMed Web of Science ®Google Scholar
• Sernicola A, Carnicelli G, Di Fraia M, et al. ‘Toxic erythema’ and eosinophilia associated with tocilizumab therapy in a COVID-19 patient. J Eur Acad Dermatol Venereol. 2020;34(8):e368–e370. doi:10.1111/jdv.16620
   PubMed Web of Science ®Google Scholar
• Mesli F, Dumont M, Soria A, et al. Benralizumab: a potential tailored treatment for life-threatening DRESS in the COVID-19 era. J Allergy Clin Immunol Pract. 2021;9:3529–3531.
   PubMed Web of Science ®Google Scholar
• Ricciardolo FLM, Bertolini F, Carriero V. The role of Dupilumab in severe asthma. Biomedicines. 2021;9(9):1096. doi:10.3390/biomedicines9091096
   PubMed Web of Science ®Google Scholar
• Förster-Ruhrmann U, Szczepek AJ, Bachert C, Olze H. COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab. J Allergy Clin Immunol. 2020;146(1):218–220. doi:10.1016/j.jaci.2020.05.005
   PubMed Web of Science ®Google Scholar
• Ferrucci S, Romagnuolo M, Angileri L, Berti E, Tavecchio S. Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports. J Eur Acad Dermatol Venereol. 2020;34(7):e303–e304. doi:10.1111/jdv.16527
   PubMed Web of Science ®Google Scholar
• Caroppo F, Biolo G, Belloni Fortina A. SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab. J Eur Acad Dermatol Venereol. 2020;34(8):e368. doi:10.1111/jdv.16619
   PubMed Web of Science ®Google Scholar
• Bhalla A, Mukherjee M, Radford K, et al. Dupilumab, severe asthma airway responses, and SARS-CoV-2 serology. Allergy. 2021;76(3):957–958. doi:10.1111/all.14534
   PubMed Web of Science ®Google Scholar
• Rossi M, Rovati C, Arisi M, Soglia S, Calzavara-Pinton P. Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: a single-center real-life experience. Dermatol Ther. 2020;33:e13765. doi:10.1111/dth.13765
   PubMed Web of Science ®Google Scholar
• Ordóñez-Rubiano MF, Campo I, Casas M. Dupilumab in atopic dermatitis, a protocol for SARS-COV-2-infected patients. Dermatol Ther. 2020;33:e14172. doi:10.1111/dth.14172
   PubMed Web of Science ®Google Scholar
• Ordóñez-Rubiano MF, Rubiano-Mojica PC, Casas M. Young HIV-positive male patient with severe atopic dermatitis on dupilumab and SARS-CoV-2 infection, a pioneer hypothesis. Int J Dermatol. 2021;60(4):514–515. doi:10.1111/ijd.15499
   PubMed Web of Science ®Google Scholar
• Tanabe N, Matsumoto H, Hamada S, Ito I, Hirai T. Dupilumab maintenance therapy in an asthmatic patient with coronavirus disease 2019 pneumonia. Allergol Int. 2021;70(2):274–276. doi:10.1016/j.alit.2020.10.005
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Talamonti M, De Simone C, et al.; DA‐COVID‐19 study group. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry. Allergy. 2021;76(6):1813–1824. doi:10.1111/all.14767
   PubMed Web of Science ®Google Scholar
• Stingeni L, Hansel K, Antonelli E, et al. Atopic dermatitis in adolescents: effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy. Dermatol Ther. 2021;34(5). doi:10.1111/dth.15035.
   Web of Science ®Google Scholar
• Hansel K, Patruno C, Antonelli E, et al. Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic. Clin Exp Dermatol. 2021. doi:10.1111/ced.14862
   Web of Science ®Google Scholar
• Ceryn J, Niedźwiedź M, Skibińska M, Ciążyńska M, Lesiak A, Narbutt J. COVID-19 in patients with atopic dermatitis treated with Dupilumab: three cases and a literature review. Clin Cosmet Investig Dermatol. 2021;14:1131–1138. doi:10.2147/CCID.S321003
   PubMed Web of Science ®Google Scholar
• Menzella F, Ghidoni G, Galeone C, Capobelli S, Scelfo C, Facciolongo NC. Immunological aspects related to viral infections in severe asthma and the role of Omalizumab. Biomedicines. 2021;9(4):348. doi:10.3390/biomedicines9040348
   PubMed Web of Science ®Google Scholar
• Gonzales-van Horn SR, Farrar JD. Interferon at the crossroads of allergy and viral infections. J Leukoc Biol. 2015;98(2):185–194. doi:10.1189/jlb.3RU0315-099R
   PubMed Web of Science ®Google Scholar
• Gern JE. How rhinovirus infections cause exacerbations of asthma. Clin Exp Allergy. 2015;45(1):32–42. doi:10.1111/cea.12428
   PubMed Web of Science ®Google Scholar
• Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476–1485. doi:10.1016/j.jaci.2015.09.008
   PubMed Web of Science ®Google Scholar
• Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158–168. doi:10.1016/j.cell.2020.08.017
   PubMed Web of Science ®Google Scholar
• Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463–469. doi:10.1038/s41586-020-2588-y
   PubMed Web of Science ®Google Scholar
• Donlan AN, Sutherland TE, Marie C, et al. IL-13 is a driver of COVID-19 severity. JCI Insight. 2021;6(15):e150107. doi:10.1172/jci.insight.150107
   PubMed Web of Science ®Google Scholar
• Poddighe D, Mathias CB, Brambilla I, Marseglia GL, Oettgen HC. Importance of basophils in eosinophilic asthma: the murine counterpart. J Biol Regul Homeost Agents. 2018;32(2):335–339.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Di Gioacchino M, Greco M, et al. Basophils and mast cells in COVID-19 pathogenesis. Cells. 2021;10(10):2754. doi:10.3390/cells10102754
   PubMed Web of Science ®Google Scholar
• Huang J, Zhang Z, Liu S, et al. Absolute eosinophil count predicts intensive care unit transfer among elderly COVID-19 patients from general isolation wards. Front Med. 2020;7:585222. doi:10.3389/fmed.2020.585222
   Web of Science ®Google Scholar
• Farmani AR, Mahdavinezhad F, Moslemi R, et al. Anti-IgE monoclonal antibodies as potential treatment in COVID-19. Immunopharmacol Immunotoxicol. 2021;43(3):259–264.doi:10.1080/08923973.2021.1925906
   PubMed Web of Science ®Google Scholar
• Grieco T, Porzia A, Paolino G, et al. IFN-γ/IL-6 and related cytokines in chronic spontaneous urticaria: evaluation of their pathogenetic role and changes during omalizumab therapy. Int J Dermatol. 2020;59(5):590–594. doi:10.1111/ijd.14812
   PubMed Web of Science ®Google Scholar
• Poddighe D, Vangelista L. Effects of omalizumab on basophils: potential biomarkers in asthma and chronic spontaneous urticaria. Cell Immunol. 2020;358:104215. doi:10.1016/j.cellimm.2020.104215
   PubMed Web of Science ®Google Scholar
• Ando T, Kitaura J. Tuning IgE: IgE-associating molecules and their effects on IgE-dependent mast cell reactions. Cells. 2021;10(7):1697. doi:10.3390/cells10071697
   PubMed Web of Science ®Google Scholar
• Pala D, Pistis M. Anti-IL5 drugs in COVID-19 patients: role of Eosinophils in SARS-CoV-2- induced immunopathology. Front Pharmacol. 2021;12:622554. doi:10.3389/fphar.2021.622554
   PubMed Web of Science ®Google Scholar
• Flores-Torres AS, Salinas-Carmona MC, Salinas E, Rosas-Taraco AG. Eosinophils and respiratory viruses. Viral Immunol. 2019;32(5):198–207. doi:10.1089/vim.2018.0150
   PubMedGoogle Scholar
• Rodrigo-Muñoz JM, Gil-Martínez M, Sastre B, Del Pozo V. Emerging evidence for pleiotropism of Eosinophils. Int J Mol Sci. 2021;22:7075. doi:10.3390/ijms22137075
   PubMed Web of Science ®Google Scholar
• Damiani S, Fiorentino M, de Palma A, et al. Pathological postmortem findings in lungs infected with SARS-CoV-2. J Pathol. 2020;253:31–40. doi:10.1002/path.5549
   PubMed Web of Science ®Google Scholar
• Luecke E, Jeron A, Kroeger A, et al. Eosinophilic pulmonary vasculitis as a manifestation of the hyperinflammatory phase of COVID-19. J Allergy Clin Immunol. 2021;147(1):112–113. doi:10.1016/j.jaci.2020.09.026
   PubMed Web of Science ®Google Scholar
• Murao K, Saito A, Kuronuma K, Fujiya Y, Takahashi S, Chiba H. Acute eosinophilic pneumonia accompanied with COVID-19: a case report. Respirol Case Rep. 2020;8(9):e00683. doi:10.1002/rcr2.683
   PubMed Web of Science ®Google Scholar
• Smola A, Samadzadeh S, Müller L, et al. Omalizumab prevents anaphylactoid reactions to mRNA COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021;35(11):e743–e745. doi:10.1111/jdv.17549
   PubMed Web of Science ®Google Scholar
• Colaneri M, De Filippo M, Licari A, et al. COVID vaccination and asthma exacerbation: might there be a link? Int J Infect Dis. 2021;112:243–246. doi:10.1016/j.ijid.2021.09.026
   PubMed Web of Science ®Google Scholar